Indomethacin (NSC-77541)

Catalog No.S1723 Synonyms: Indometacin

For research use only.

Indomethacin (NSC-77541, Indometacin) is a nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively, used to reduce fever, pain, stiffness, and swelling.

Indomethacin (NSC-77541) Chemical Structure

CAS No. 53-86-1

Selleck's Indomethacin (NSC-77541) has been cited by 13 publications

Purity & Quality Control

Choose Selective COX Inhibitors

Other COX Products

Biological Activity

Description Indomethacin (NSC-77541, Indometacin) is a nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively, used to reduce fever, pain, stiffness, and swelling.
Targets
COX1 [6] COX-2 [6]
0.28 μM 14 μM
In vitro

Indomethacin inhibits transcription of a beta-catenin/TCF-responsive reporter gene in a dose dependent manner. Indomethacin also downregulates the beta-catenin/TCF transcriptional target cyclin D1. Indomethacin attenuates the transcription of beta-catenin/TCF-responsive genes, by modulating TCF activity without disrupting beta-catenin/TCF complex formation. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HeLa cells MoLFSpVv[3Srb36gZZN{[Xl? NFTkUG0zOCCvaX7z MX7B[49vcXO2IHHjeIl3cXS7IHH0JIFv\HKxZ3XuJJJm[2WydH;yJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKEinTHGgZ4VtdHNiY3:t[ZhxemW|c3nu[{BRW0FvKFHSSUk1NUy3Y{GzJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDETHQucW6mdXPl[EBtfWOrZnXyZZNmKGGldHn2bZR6KGGodHXyJFIxKG2rboOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxRTBwMUSgcm0> NVXVS4U3OjN2M{KwPVU>
J774 cells NF7Y[WhHfW6ldHnvckBie3OjeR?= NVTDXIZLUW5idnn0do8hcW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KFC{b4P0ZYdt[W6maX6gS{9JKHO7boToZZNmKDFiaX6gcZVzcW6nIFq3O|Qh[2WubIOsJGlEPTB;MjDuUS=> MUmxOVg2PzF2OR?=
U-937 cells Mnz5SpVv[3Srb36gZZN{[Xl? NUHUTll[UW5idnn0do8hcW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJHBzd3O2YXfsZY5lcW5iRz;IJJN6dnSqYYPlJFEhMEORWD2xLUBqdiCXLUmzO{Bk\WyuczygTWM2OD1{IH7N NX7JOHBpOTJ6N{e1PFQ>
rat synovial cells NFn3OJdHfW6ldHnvckBie3OjeR?= MUXJckB3cXS{bzDpcohq[mm2b4L5JIVn\mWldDDvckBxem:mdXP0bY9vKG:oIIDyc5N1[WeuYX7kbY4hTTJiKGDHSVIqKGmwIILheEB{gW6xdnnhcEBk\WyuczygTWM2OD1{Lkmgcm0> MmTNNVA5OjF5MU[=
143982 cells NFGxRoxHfW6ldHnvckBie3OjeR?= NYHic25PUW5idnn0do8hcW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJHBzd3O2YXfsZY5lcW5iRz;IJJN6dnSqYYPlJFIhMEORWD2yLUBqdiBzNEO5PFIh[2WubIOsJGlEPTB;OTDuUS=> M{TWO|EzQDd5NUi0
CHO cells Mo\iSpVv[3Srb36gZZN{[Xl? M13EOWlvKH[rdILvJIlvcGmkaYTvdpkheG:2ZX7jfUBi\2GrboP0JIh2dWGwIFPPXE0yKGmwIIP0ZYJtgSC2cnHud4Zm[3SnZDDjbIlv\XOnIHjhcZN1\XJib4\hdpkhMEOKTzmgZ4VtdHNuIFnDOVA:OThibl2= NXe5W4xtOTB3N{[2PFQ>
RBL-1 cell line MWDGeY5kfGmxbjDhd5NigQ>? NF7jTldKdmirYnn0bY9vKG:oIGDyc5N1[WeuYX7kbY4hTy:KIIP5cpRp[XOnIHnuJIlvfGGldDDSRmwuOSClZXzsJIxqdmVuIFnDOVA:OC53IN88US=> NUj1dW1ZOjFzNUW4Oi=>
SF-9 insect cells M4jE[mZ2dmO2aX;uJIF{e2G7 MVmyNEBOcW6| MUnJcohq[mm2aX;uJI9nKGi3bXHuJGNQYDJiZYjwdoV{e2WmIHnuJHNHNTliaX7z[YN1KGOnbHzzJIF{e2W|c3XkJIF{KGOxbo\ldpNqd25ib3[gX|E1S11vYYLhZ4hq\G:waXOgZYNq\CC2bzDbNVREZS2ycn;zeIFodGGwZHnud{BxemWrbnP1ZoF1\WRiZn;yJFIxKG2rboOgZpkhfGirbj3sZZlmeiClaILvcYF1d2e{YYDofUBidmGueYPpd{whUUN3ME2wMlc2KM7:TR?= MVqyNVUzPDV6Nx?=
mouse RAW264.7 cells M4LYUWZ2dmO2aX;uJIF{e2G7 NELTWogzPCCq NFK2Z5VCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJHJCXzJ4ND63JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgUm8heHKxZIXjeIlwdiCjZoTldkAzPCCqcoOgZpkhT3KrZYPzJIF{e2G7LDDJR|UxRTFwMkWg{txO NVPWRYhCOjR6ME[zNVA>
mouse BV2 cells M{LZbWZ2dmO2aX;uJIF{e2G7 NYjGOZRMOjRiaB?= NUDlXnlpSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBDXjJiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBNWFNvaX7keYNm\CCQTzDwdo9lfWO2aX;uJIFnfGW{IEK0JIhzeyCkeTDHdolme3NiYYPzZZktKEmFNUC9O{4yKM7:TR?= M3XCVVI1ODR{MEC3
human 2008 cells NYjwXWp1TnWwY4Tpc44h[XO|YYm= NWTPbXp4UW6qaXLpeIlwdiCxZjDoeY1idiCPUmCxJIlvKGi3bXHuJFIxODhiY3XscJMtKEmFNUC9NVIh|ryP NFjqSosyQDdyN{i4OC=>
A549 cells  MmDpSpVv[3Srb36gZZN{[Xl? MVmxNEDPxE1? NHXZOHBKdmirYnn0bY9vKG:oIH3QS2VUOSCrbjDoeY1idiCDNUS5JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiSVytNU1j\XSjLXnu[JVk\WRiUFfFNkBnd3KvYYTpc44h[XRiMUCgeW0h[nliY3XscE1qdnSjY4SgZZN{[Xl? MWKxPVA2Ozd3MR?=
HepG2 cells NH\OS4VHfW6ldHnvckBie3OjeR?= MVWxNFAh|ryP M{nNcWlvcGmkaYTpc44hd2ZiTWLQNU1u\WSrYYTl[EBld3ixcoXibYNqdiCnZn\seZghcW5iZH;4c5J2[mmlaX6gdoV{cXO2YX70JIh2dWGwIFjldGczKGOnbHzzJIF1KDFyMDD1UUBjgSCobH;3JIN6fG:vZYTyfS=> NF;wcmozODR3NUW3PC=>
THP1 cells NV3xSG1bTnWwY4Tpc44h[XO|YYm= MW[xNFAh|ryP NFrKU3k{OCCvaX7z M2m2UWlzemW4ZYLzbYJt\SCrbnjpZol1cW:wIH;mJGNQYC1zIHnuJIh2dWGwIGTIVFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhdoFkcGmmb37pZ{Bi[2mmLXnu[JVk\WRiVGjCNkBnd3KvYYTpc44h[XRiMUCwJJVOKGmwY4XiZZRm\CCob4KgN|AhdWmwczDmc4xtd3enZDDifUBkd22yb4Xu[EB4[XOqb4X0JI1m[XO3cnXkJFMxKG2rboOgdI9{fCCjcnHjbIlld26rYzDhZ4llKGOqYXzs[Y5o\SCkeTDyZYRqd2mvbYXuc4F{e2G7 M{jwXlI{PjVzM{W5
MDA-MB-231 cells NUD2NWx[TnWwY4Tpc44h[XO|YYm= NGLRUVQyODBizszN M1Ps[lMxKG2rboO= MV;JdpJmfmW{c3nicIUhcW6qaXLpeIlwdiCxZjDDU3guOSCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[XKjY3jp[I9vcWNiYXPp[E1qdmS3Y3XkJHBITTJiZn;ycYF1cW:wIHH0JFExOCC3TTDpcoN2[mG2ZXSg[o9zKDNyIH3pcpMh\m:ubH;3[YQh[nliY3;tdI92dmRid3HzbI92fCCvZXHzeZJm\CB|MDDtbY5{KHCxc4SgZZJi[2irZH;ubYMh[WOrZDDjbIFtdGWwZ3WgZpkhemGmaX;pcY12dm:jc4PhfS=> M{jsNFI{PjVzM{W5
LNCAP cells NIfORmRHfW6ldHnvckBie3OjeR?= NIrIcGo{OCEQvF2= M4G0eVQ5KGh? M{jSbWlvcGmkaYTpc44hd2ZiQVvSNWM{KCi3bnvuc5dvKG:{aXfpckkudWWmaXH0[YQhfGW|dH;zeIVzd26nLUG3ZoV1[S2pbIXjeZJwdmmmZTDmc5Ju[XSrb36g[ZhxemW|c3XkJIlvKGi3bXHuJGxPS0GSIHPlcIx{KGG2IEOwJJVOKGGodHXyJFQ5KGi{czDpckBxemW|ZX7j[UBw\iB2LXHu[JJwe3SnbnWtN{wyPy2maX;u[S=> M2jBOlI{PDN{MEm1
mouse BV2 cells NHLUZVZEgXSxdH;4bYNqfHliYYPzZZk> MVuyOEBp NX3WOlFXS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSlZ{IHPlcIx{KGG|c3Xzd4VlKGG|IH3hfIlufW1ibn;uMZRwgGmlIHPvcoNmdnS{YYTpc44h[W[2ZYKgNlQhcHK|IHL5JG1VXCCjc4PhfS=> M1jUVlI{PzFzOUG3
In vivo Indomethacin increases BrdU+ cells of all lineages and reduces microglial/monocyte activation in rats after focal cerebral ischemia. [2] Indomethacin (7.5 mg/kg, one injection) produces acute injury and inflammation in the distal jejunum and proximal ileum that are maximal at three days and completely resolves within one week. Indomethacin (two daily subcutaneous injections) produces a more extensive and chronic inflammation that lasts in an active form in more than 75% of the rats for at least two weeks. [3] Indomethacin (4ppm) reduces tumor yield by 78% in SKH:HR-1-hrBr hairless mice. [4] Indomethacin (20 mg/kg, orally) increases the total area of gastric erosions and concentration of lipid peroxides in the gastric mucosa of rats. Indomethacin increases the alpha-tocopherol:total cholesterol ratio in serum. Indomethacin inhibits the increases in gastric mucosal erosions and lipid peroxides in the gastric mucosa, and the reduction of serum alpha-tocopherol. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.

2mg/mL

Chemical Information

Molecular Weight 357.79
Formula

C19H16ClNO4

CAS No. 53-86-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04821323 Completed Drug: Indomethacin|Diagnostic Test: Lactulose-mannitol Healthy Janssen Research & Development LLC March 10 2021 Early Phase 1
NCT04025177 Withdrawn Drug: Indomethacin Injection Patent Ductus Arteriosus After Premature Birth University of Manitoba|St. Boniface Hospital|Health Sciences Centre Winnipeg Manitoba|University at Buffalo January 2020 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Indomethacin (NSC-77541) | Indomethacin (NSC-77541) supplier | purchase Indomethacin (NSC-77541) | Indomethacin (NSC-77541) cost | Indomethacin (NSC-77541) manufacturer | order Indomethacin (NSC-77541) | Indomethacin (NSC-77541) distributor